About new long-term vision “Vision 110”
To embody our corporate philosophy—“Kyorin shall fulfill its social mission of contributing to better health by cherishing life”—the Group is advancing its long-term vision, "Vision 110" (FY2023-2032), leading up to our 110th anniversary in 2033.Our envisioned goal is to become "a company that contributes broadly to people's health by positioning the innovative drug business—which continuously provides high-value new drugs that meet medical needs—as its core, while simultaneously developing a diverse range of health-related businesses."
We are fully committed to making this vision a reality.The "Vision 110" initiative is being implemented in three stages (Stage 1: FY2023-2025; Stage 2: FY2026-2029; and Stage 3: FY2030-2032). Following the conclusion of the first phase, "Vision 110 -Stage 1-," in fiscal 2025, we have officially launched the new medium-term business plan, "Vision 110 -Stage 2-," as of fiscal 2026.
Long-term Vision
Vision for 110th anniversary
- Our goal
-
A company that contributes broadly to people's health by comprehensively developing healthcare-related businesses, with a core focus on the new drug business, which continuously provides high-value new drugs that meet medical needs
- Term
-
10 years: FY2023 - FY2032
- Medium-term business plan
-
- Stage1FY2023 - FY2025
- Stage2FY2026 - FY2029
- Stage3FY2030 - FY2032